Neurorescuing effects of the GAPDH ligand CGP 3466B

Journal of Neural Transmission, Supplement

Volumn 60, Issue , 2000, Pages 197-214

  Waldmeier, P C ^a   Boulton, A A ^b   Cools, A R ^c   Kato, A C ^d   Tatton, W G ^e  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 10 (N METHYL N PROPARGYLAMINOMETHYL)DIBENZO[B,F]OXEPIN; APOPTOSIS INHIBITOR; CGP 3466A; CGP 3466B; DIBENZO[B,F]OXEPIN 10 YLMETHYL METHYLPROP 2 YNYL AMINE; MONOAMINE OXIDASE B INHIBITOR; OXIDOPAMINE; SELEGILINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; MALE; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANIMALS, NEWBORN; BRAIN; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; LIGANDS; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; OXEPINS; PARKINSON DISEASE; RATS; RATS, WISTAR; SELEGILINE;

EID: 0034523131     PISSN: 03036995     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-3-7091-6301-6_13     Document Type: Article

References (76)

1. Paw reaching in rats: The staircase test
2. Systemic administration of CGP 3466B prevents enzymatic and behavioral deficits in 6-OHDA treated rats
3. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: Stereospecificity and independence from monoamine oxidase inhibition
4. L-deprenyl does not reduce brain damage in global forebrain ischemia in adult gerbils (Meriones ungiculatus)
5. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush
6. Selegiline in Parkinson's disease - No neuroprotective effect: Increased mortality
7. Reduced apoptosis after NGF and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer
8. Role of oxidative stress in the manganese and 1-methyl-4-(2′-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced apoptosis in PC12 cells
9. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B
10. Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)Deprenyl, following kainic acid administration
11. Is selegiline neuroprotective in Parkinson's disease?
12. Pharmacology of selegiline
13. Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease
14. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons
15. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture
16. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture
17. Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis
18. Deprenyl and pergolide rescue spinal motor neurons from axotomy-induced neuronal death in the neonatal rat
19. CGP 3466B, a dibenzoxepine derivative, increases life-span in an animal model of motoneuron disease
20. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
21. L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia
22. Neuroprotective therapy for Parkinson's disease
23. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium
24. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl
25. Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus
26. +)-induced apoptosis independent of MAO-B inhibition
27. Neuroprotection by anti-oxidant strategies in Parkinson's disease
28. Clinical pharmacokinetics and pharmacodynamics of selegiline - An update
29. (-)-deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide
30. Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: Effects of simultaneously administered nomifensine, deprenyl, and t-butyl-4,4-diphenylpiperidine
31. The "staircase test": A measure of independent forelimb reaching and grasping abilities in rats
32. (-)-deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures
33. Deprenyl protects dopamine neurons from neurotoxic effects of 1-methyl-4-phenylpyridinium ion
34. L-deprenyl protects mesencephalic dopaminergic neurons from glutamate receptor-mediated toxicity in vitro
35. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro
36. Early therapy for Parkinson's disease
37. Current status of selegiline as a neuroprotective agent in Parkinson's disease
38. Antiapoptotic actions of monoamine oxidase B inhibitors
39. (-)-deprenyl reduces delayed neuronal death of hippocampal pyramidal cells
40. CGP 3466 and CGP 3466B prevent cytosine arabinoside-induced apoptosis in cultures of cerebellar neurones
41. CGP3466 prevents neuronal death in models of ischaemia and seizure in vivo
42. R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium
43. L-deprenyl protects injured retinal precursor cells in vitro
44. (-)deprenyl attenuates spinal motor neuron degeneration and associated locomotor deficits in rats subjected to spinal cord ischemia
45. Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic nigrostriatal system but fails to counteract axotomy-induced degenerative changes
46. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease
47. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons
48. Deprenyl increases survival of rat foetal nigral neurones in culture
49. Clinical and molecular views on motor neuron disease: Animal models, neurotrophic factors and bcl-2 oncoprotein
50. Deprenyl reduces the death of facial motoneurons damaged by axotomy in early life
51. Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity
52. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis
53. Glyceraldehyde-3-phosphate dehydrogenase: Nuclear translocation participates in neuronal and nonneuronal cell death
54. +) neurotoxicity by deprenyl in organotypic canine Substantia nigra cultures
55. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic [see comments]
56. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage
57. Nuclear translocation of GAPDH-GFP fusion protein during apoptosis
58. Deprenyl rescues dopaminergic neurons in organotypic slice cultures of neonatal rat mesencephalon from N-methyl-D-aspartate toxicity
59. DATATOP: A decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism
60. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration
61. Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
62. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis
63. Reduction of neuronal apoptosis by small molecules: Promise for new approaches to neurological therapy
64. Apoptosis in neurodegenerative disorders: Potential for therapy by modifying gene transcription
65. L-deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse
66. Increased neuronal cell survival after 1-deprenyl treatment in experimental thiamine deficiency
67. Diphenylpiperazines enhance regeneration after facial nerve injury
68. L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenyl pyridinium ion
69. Deprenyl's neuroprotective action remains unresolved
70. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl
71. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease
72. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study
73. Specific antiapoptotic activity of the neurorescuing compound TCH346
74. + in vivo
75. + dopaminergic toxicity
76. CNTF or (-)-deprenyl in immature rats: Survival of axotomized facial motoneurons and weight loss